CRISPR Therapeutics Q1 2025 net loss $136M; CTX310 Phase 1 shows up to 82% TG reduction

CRISPR Therapeutics AG

2025-Q1 EPS reported -$1.58 revenue$865,000

Net loss of $136.0M in Q1 2025, compared to $116.6M in Q1 2024; cash & equivalents $1.86B.
CTX310 Phase 1 data: dose-dependent reductions in LDL (up to 81%) and TG (up to 82%) with well-tolerated safety.
CASGEVY: >65 authorized treatment centers activated; ~90 patients with first cell collection; new initiations to grow in 2025.
R&D expenses $72.5M, G&A $19.3M; collaboration expense net $57.5M (driven by CASGEVY and in vivo HSC editing).
CTX320 (Lp(a)) dose escalation ongoing with update expected Q2 2025; CTX112/CTX131 CAR T updates mid-2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.